ArticleACS omega2024
MVGNet: Prediction of PI3K Inhibitors Using Multitask Learning and Multiview Frameworks.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design of novel PI3Kα and PI3Kγ inhibitors for cancer treatment using pharmacophore, protein-ligand contacts, and machine learning methods.Journal of computer-aided molecular design · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PI3K (phosphatidylinositol 3-kinase) is an intracellular phosphatidylinositol kinase composed of a regulatory subunit, p85, and a catalytic subunit, p110. Based on the different structures of the p110 catalytic subunit, PI3K can be divided into four isoforms: PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ. As molecularly targeted drugs, PI3K inhibitors have demonstrated antiproliferative effects on tumor cells and can also induce cancer cell death. In this study, a multiview deep learning framework (MVGNet) is proposed, which integrates fragment-based pharmacophore information and utilizes multitask learning to capture correlation information between subtasks. This framework predicts the inhibitory activity of molecules against the four PI3K isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Compared to baseline prediction models based on three traditional machine learning methods (RF, SVM, and XGBoost) and four deep learning algorithms (GAT, D-MPNN, CMPNN, and KANO), our model demonstrates superior performance. The evaluation results show that our model achieves the highest average AUC-ROC and AUC-PR values on the test set, which are 0.927 ± 0.006 and 0.980 ± 0.002, respectively. This study provides a reference for exploring the structure-activity relationship of PI3K inhibitors.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.